Literature DB >> 26944099

PK/PD analysis of a novel pH-dependent antigen-binding antibody using a dynamic antibody-antigen binding model.

Kenta Haraya1, Tatsuhiko Tachibana2, Yuki Iwayanagi3, Atsuhiko Maeda3, Kazuhisa Ozeki3, Junichi Nezu2, Masaki Ishigai3, Tomoyuki Igawa3.   

Abstract

Previously, we have reported novel engineered antibody with pH-dependent antigen-binding (recycling antibody), and with both pH-dependent antigen-binding and increased FcRn-binding at neutral pH (sweeping antibody). The purpose of this study is to perform PK/PD predictions to better understand the potential applications of the antibodies as therapeutics. To demonstrate the applicability of recycling and sweeping antibodies over conventional antibodies, PK/PD analyses were performed. PK/PD parameters for antibody and antigen dynamics were estimated from the results of a pharmacokinetic study in human FcRn transgenic mice. A simulation study was performed using the estimated PK/PD parameters with various target antigen profiles. In comparison to conventional antibody, recycling antibody enhanced antibody-antigen complex clearance by 3 folds, while sweeping antibody accelerated antigen clearance by 10 folds in a pharmacokinetic study. Simulation results showed that recycling and sweeping antibodies can improve dosage frequency and reduce the required dose for target antigens with various clearances, plasma concentrations or binding kinetics. Moreover, importance of the association rate constant to enhance the beneficial effect of antibodies was shown. These results support the conclusion that recycling and sweeping antibodies can be applied to various target antigens with different profiles, and expand the number of antigens that antibodies can target.
Copyright © 2016 The Japanese Society for the Study of Xenobiotics. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  FcRn; Monoclonal antibody; PK/PD; TMDD; pH-dependent antigen-binding

Mesh:

Substances:

Year:  2016        PMID: 26944099     DOI: 10.1016/j.dmpk.2015.12.007

Source DB:  PubMed          Journal:  Drug Metab Pharmacokinet        ISSN: 1347-4367            Impact factor:   3.614


  8 in total

1.  A Minimal Physiologically Based Pharmacokinetic Model with a Nested Endosome Compartment for Novel Engineered Antibodies.

Authors:  Dongfen Yuan; Frederik Rode; Yanguang Cao
Journal:  AAPS J       Date:  2018-03-14       Impact factor: 4.009

2.  Simple Approach to Accurately Predict Pharmacokinetics of Therapeutic Monoclonal Antibodies after Subcutaneous Injection in Humans.

Authors:  Kenta Haraya; Tatsuhiko Tachibana
Journal:  Clin Pharmacokinet       Date:  2021-01       Impact factor: 6.447

3.  Identification of human IgG1 variant with enhanced FcRn binding and without increased binding to rheumatoid factor autoantibody.

Authors:  Atsuhiko Maeda; Yuki Iwayanagi; Kenta Haraya; Tatsuhiko Tachibana; Genki Nakamura; Takeru Nambu; Keiko Esaki; Kunihiro Hattori; Tomoyuki Igawa
Journal:  MAbs       Date:  2017-04-07       Impact factor: 5.857

4.  Maximizing in vivo target clearance by design of pH-dependent target binding antibodies with altered affinity to FcRn.

Authors:  Danlin Yang; Craig Giragossian; Steven Castellano; Marcio Lasaro; Haiguang Xiao; Himanshu Saraf; Cynthia Hess Kenny; Irina Rybina; Zhong-Fu Huang; Jennifer Ahlberg; Tammy Bigwarfe; Maria Myzithras; Erica Waltz; Simon Roberts; Rachel Kroe-Barrett; Sanjaya Singh
Journal:  MAbs       Date:  2017-08-08       Impact factor: 5.857

5.  Antibodies to watch in 2017.

Authors:  Janice M Reichert
Journal:  MAbs       Date:  2016-12-14       Impact factor: 5.857

6.  Antibody engineering to generate SKY59, a long-acting anti-C5 recycling antibody.

Authors:  Zenjiro Sampei; Kenta Haraya; Tatsuhiko Tachibana; Taku Fukuzawa; Meiri Shida-Kawazoe; Siok Wan Gan; Yuichiro Shimizu; Yoshinao Ruike; Shu Feng; Taichi Kuramochi; Masaru Muraoka; Takehisa Kitazawa; Yoshiki Kawabe; Tomoyuki Igawa; Kunihiro Hattori; Junichi Nezu
Journal:  PLoS One       Date:  2018-12-28       Impact factor: 3.240

Review 7.  Modeling Pharmacokinetics and Pharmacodynamics of Therapeutic Antibodies: Progress, Challenges, and Future Directions.

Authors:  Yu Tang; Yanguang Cao
Journal:  Pharmaceutics       Date:  2021-03-21       Impact factor: 6.321

8.  Estimation of Clearance and Bioavailability of Therapeutic Monoclonal Antibodies from Only Subcutaneous Injection Data in Humans Based on Comprehensive Analysis of Clinical Data.

Authors:  Kenta Haraya; Tatsuhiko Tachibana
Journal:  Clin Pharmacokinet       Date:  2021-05-06       Impact factor: 6.447

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.